Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Roche gets ex-US rights to Sarepta’s DMD gene therapy SRP9001

Executive Summary

In its second significant gene therapy investment of 2019, Roche gained exclusive commercial rights outside of the US to Sarepta Therapeutics Inc.’s Phase I/II gene therapy SRP9001 (AAVrh74.MHCK7.micro-dystrophin) for Duchenne muscular dystrophy, a rare neuromuscular disease. The deal comes just days after Roche finally closed its acquisition of gene therapy developer Spark Therapeutics after announcing the transaction in January.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies